+142.6%
BKNG vs MRNA
+521.0%
-378.4%
-44.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.5% | +0.7% | -0.2% | +0.5% |
| 7D | -10.7% | -8.2% | -2.4% | -10.5% |
| 30D | -18.1% | +125.6% | -143.7% | -21.2% |
| 3M | +8.5% | +197.1% | -188.5% | +3.3% |
| 6M | -0.1% | +148.5% | -148.5% | -4.4% |
| YTD | -18.2% | +363.3% | -381.5% | -23.5% |
| 1Y | -19.9% | +462.0% | -481.9% | -25.6% |
| 3Y | +41.6% | +26.9% | +14.7% | +34.9% |
| 5Y | +93.1% | -69.6% | +162.7% | +81.8% |
| All | +142.6% | +521.0% | -378.4% | +130.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling